Could a diabetes drug curb alcohol cravings in schizophrenia?

NCT ID NCT06939088

First seen Jan 11, 2026 · Last updated Apr 28, 2026 · Updated 18 times

Summary

This study tests whether tirzepatide, a drug used for diabetes and obesity, can reduce heavy drinking in people who have both schizophrenia and alcohol use disorder. About 108 participants will receive either tirzepatide or a placebo for 16 weeks. Researchers will also use brain scans to see if the drug changes how the brain responds to alcohol cues.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Psychiatry, Aalborg University Hospital

    RECRUITING

    Aalborg, Denmark, 9000, Denmark

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Psychiatric Center Copenhagen, Frederiksberg Hospital

    RECRUITING

    Frederiksberg, Denmark, 2100, Denmark

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.